Classement en actions
#26169
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in... Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
Capitalisation boursière
$42.88M
Changement (1 jour)
2.16%
Changement (1 an)
-18.85%
Échange Molecure S.A. (MOC)
Le prix MOC avec la capitalisation boursière de B
Capitalisation boursière de Molecure S.A.(MOC)
Capitalisation boursière: $42.88M
En August 2026, Molecure S.A. a une capitalisation boursière de $42.88M. Cela fait de Molecure S.A. la 26169th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Molecure S.A. du 2018 au 2026
MOC par rapport au top 5 des plus populaires stocks
| Prix pour MOC |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.242T
|
+12,225,855.89%
|
|
|
|
|
$4.650T
|
+10,846,038.05%
|
|
|
|
|
$4.111T
|
+9,588,261.83%
|
|
|
|
|
$3.578T
|
+8,344,314.81%
|
|
|
|
|
$2.812T
|
+6,558,242.86%
|
